1.
Org Lett
; 8(24): 5449-52, 2006 Nov 23.
Artigo
em Inglês
| MEDLINE
| ID: mdl-17107044
RESUMO
Inhibition of protein synthesis is one of the validated and highly successful targets for inhibition of bacterial growth; this mechanism is a target of a large number of clinical drugs. Ribosomal protein S4, a primary protein, is a potential target for the discovery of antibacterial agents. We describe, using an antisense-sensitized rpsD Streptomyces aureus strain, the discovery and activity of lucensimycins A and B. [structure: see text].